# Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

> **NCT05742802** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1713 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **COMBINATION_PRODUCT:** Tozorakimab 1
- **COMBINATION_PRODUCT:** Tozorakimab 2
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT05742802
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-06
- **Primary completion:** 2026-02-26
- **Final completion:** 2026-05-28
- **Target enrollment:** 1713 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05742802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05742802, "Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05742802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*